Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
AstraZeneca PLC, commonly referred to as AstraZeneca, is a leading global pharmaceutical company headquartered in the United Kingdom. Established in 1999 through the merger of Astra AB and Zeneca Group, the company has a rich history of innovation in the pharmaceutical preparation manufacturing industry. With major operations across Europe, North America, and other regions, AstraZeneca specialises in developing prescription medicines across various therapeutic areas, including oncology, cardiovascular, and respiratory health.
The company is renowned for its commitment to scientific research and its portfolio of innovative, high-quality products that address unmet medical needs. AstraZeneca’s market position is strengthened by its focus on cutting-edge biopharmaceuticals and its contributions to global health. As a key player in the pharmaceutical industry, AstraZeneca continues to advance medical science and improve patient outcomes worldwide.
+29 vs industry average
Astra Zeneca’s score of 69 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing has typical carbon intensity
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
AstraZeneca's commitment to climate action includes significant emissions reduction targets and a comprehensive strategy to achieve net-zero. The pharmaceutical manufacturer aims for a 98% absolute reduction in Scope 1 and 2 greenhouse gas (GHG) emissions by 2026, using a 2015 baseline. This near-term goal is part of a broader ambition to achieve net-zero emissions across its entire value chain by 2045.
For Scope 3 emissions, AstraZeneca has set targets for significant reductions, including a 50% absolute reduction by 2030 and a 90% absolute reduction by 2045, both from a 2019 baseline. Specific Scope 3 categories also have defined reduction targets, such as an 80% reduction for fuel and energy-related activities, upstream leased assets, and downstream leased assets by 2030. Additionally, the company is working towards having 95% of its suppliers by spend for purchased goods, services, and capital goods, and 50% for upstream transportation and distribution, and business travel, set their own science-based targets by 2025.
In terms of recent emissions performance, AstraZeneca reported Scope 1 emissions of approximately 180,898,000 kg CO2e for 2023 and 125,386,000 kg CO2e for 2024. For 2022, Scope 1 emissions were approximately 237,703,000 kg CO2e, and market-based Scope 2 emissions were approximately 18,491,000 kg CO2e. In 2021, Scope 1 emissions were approximately 239,468,000 kg CO2e, market-based Scope 2 emissions were about 21,135,000 kg CO2e, and total Scope 3 emissions were approximately 5,925,850,000 kg CO2e. The company also reported approximately 5,689,936,000 kg CO2e for Scope 3 emissions in 2020 and approximately 5,681,194,000 kg CO2e in 2019.
AstraZeneca is actively pursuing initiatives such as transitioning to 100% renewable electricity globally by 2025 and aims for a 100% electric road fleet by the same year. They are also developing next-generation propellants for inhaled medicines with near-zero global warming potential, significantly lower than current propellants. The company's "Ambition Zero Carbon" strategy underpins these efforts, focusing on decarbonising operations and supply chains to decouple carbon emissions from revenue growth.
Access structured emission data, company specific factors and auditable source documents
2045
AstraZeneca commits to reach net-zero greenhouse gas emissio…
AstraZeneca commits to reach net-zero greenhouse gas emissions across the value chain by FY2045.
2026
98% reduction in Scope 1
AstraZeneca commits to reduce absolute scope 1 GHG emissions 98% by FY2026 from a FY2015 base year.
2030
95% reduction in scope 3 downstream
AstraZeneca commits to reduce absolute scope 3 GHG emissions from use of sold products 95% by 2030.
See all 6 climate goals
Already have an account? Sign in now
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


Common questions about Astra Zeneca’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more